Format

Send to

Choose Destination
Nat Rev Cancer. 2019 May;19(5):289-297. doi: 10.1038/s41568-019-0133-9.

Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.

Author information

1
Memorial Sloan Kettering Cancer Center, New York, NY, USA. rudinc@mskcc.org.
2
Memorial Sloan Kettering Cancer Center, New York, NY, USA. poirierj@mskcc.org.
3
MD Anderson Cancer Center, Houston, TX, USA.
4
University of Manchester, Manchester, UK.
5
Case Western Reserve University, Cleveland, OH, USA.
6
University of Cologne, Cologne, Germany.
7
University of Texas Southwestern Medical Center, Dallas, TX, USA.
8
Vanderbilt University Medical Center, Nashville, TN, USA.
9
Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
10
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
11
Stanford University, Palo Alto, CA, USA.
12
Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, NY, USA.

Abstract

Small cell lung cancer (SCLC) is an exceptionally lethal malignancy for which more effective therapies are urgently needed. Several lines of evidence, from SCLC primary human tumours, patient-derived xenografts, cancer cell lines and genetically engineered mouse models, appear to be converging on a new model of SCLC subtypes defined by differential expression of four key transcription regulators: achaete-scute homologue 1 (ASCL1; also known as ASH1), neurogenic differentiation factor 1 (NeuroD1), yes-associated protein 1 (YAP1) and POU class 2 homeobox 3 (POU2F3). In this Perspectives article, we review and synthesize these recent lines of evidence and propose a working nomenclature for SCLC subtypes defined by relative expression of these four factors. Defining the unique therapeutic vulnerabilities of these subtypes of SCLC should help to focus and accelerate therapeutic research, leading to rationally targeted approaches that may ultimately improve clinical outcomes for patients with this disease.

PMID:
30926931
PMCID:
PMC6538259
[Available on 2020-05-01]
DOI:
10.1038/s41568-019-0133-9
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center